Tarivid Ophthalmic Adverse Reactions

Adverse reactions to this drug were reported in 44 of 13,329 patients evaluated before and after approval (0.33%). The major adverse reactions were eye irritation in 11 patients (0.08%), eyelid itching in 8 patients (0.06%), blepharitis in 6 patients (0.05%), conjunctival injection in 5 patients (0.04%), eye pain 5 patients (0.04%), swelling of eyelid in 5 patients (0.04%), etc. [At the end of the re-examination period].
Clinically significant adverse reactions ("rarely": <0.1%, occasionally: 5%> ≥0.1%, and no specific designation: ≥5% or incidence unknown): Shock, anaphylactoid reaction: Since shock and anaphylactoid reaction may occur, patients should be carefully observed. If any symptoms such as erythema, rash, dyspnoea, decreased blood pressure, and eyelid oedema, etc. are observed, administration should be discontinued and appropriate measures should be taken.
Other adverse reactions: If the following adverse reactions are observed, appropriate measures such as discontinuing administration should be taken. (See table.)

Click on icon to see table/diagram/image